Horng H. Chen, M.D., is a board-certified cardiologist with subspecialty certification in heart failure and transplantation, adult comprehensive echocardiography and holds the academic rank of Professor of Medicine since 2011. He did his residency in Internal Medicine and his Cardiology Clinician Investigator Fellowship at Mayo Graduate School of Medicine, Mayo Clinic. Prior to coming on staff in 2001, Dr. Chen was a Mayo Foundation Scholar in the area of heart failure research.
Dr. Chen is a NIH-funded physician scientist who has advanced the field of Cardiorenal therapeutics in the area of heart failure. He is the Co-Director of the Cardiorenal Research Laboratory which is actively involved in research to uncover new therapies for heart failure and cardiorenal syndrome. Dr. Chen has been continuously funded by the NIH since 2005 and currently holds 2 NIH RO1 grants. He was elected to the prestigious American Society of Clinical Investigation in 2012.
Dr Chen is the Co-Director for Biological Agent and Drug Innovation, Dept of Cardiology at Mayo Clinic and the Co-Founder and Chief Medical Officer of Zumbro Discovery, a biotech company formed by Mayo Medical Ventures and Broadview Ventures. The goal of Zumbro Discovery is the clinical development of the novel peptide ZD 100 for the treatment of Resistant Hypertension. Dr Chen has been awarded 7 patents and has been involved in the clinical development of 2 other biotech companies.
He has over 115 publications and was the National Principal Investigator, leading a multicenter clinical trial performed within the NHLBI Heart Failure Clinical Research Network entitled: “The ROSE Study”. The Results if the study was presented as a late breaking clinical trial at AHA Scientific Session 2013 with simultaneous publication in JAMA.
Dr. E. Wesley Ely is a professor of medicine at Vanderbilt University School of Medicine with subspecialty training in Pulmonary and Critical Care Medicine. Dr. Ely’s research has focused on improving the care and outcomes of critically ill patients with ICU-acquired brain disease (manifested acutely as delirium and chronically as acquired dementia). He is the co-director of the Center for Critical Illness, Brain dysfunction, and Survivorship (CIBS Center), which has amassed thousands of patients into cohort studies and randomized trials answering vital questions about ICU acquired brain disease and other components of ICU survivorship. His team developed the primary tool (CAM-ICU, translated into 30+ languages) which is used to measure delirium in ICU-based trials and clinically at the bedside in ICUs worldwide. Dr. Ely has been continuously federally funded (NIA and/or VA) for over 15 years. He has over 400 peer-reviewed publications.. His wife is a pathologist and together they have 3 daughters who are the light of their lives.
Eddy Fan is an associate Professor in the Interdepartmental Division of Critical Care Medicine and the Institute of Health Policy, Management and Evaluation at the University of Toronto and a Staff Intensivist at the University Health Network/Mount Sinai Hospital. Dr. Fan received his undergraduate degree from the University of Toronto, his medical degree from the University of Western Ontario and a PhD in Clinical Investigation from Johns Hopkins University. He is currently the Medical Director of the Extracorporeal Life Support Program at the Toronto General Hospital, and the Director of Critical Care Research at the University Health Network/Mount Sinai Hospital. Dr. Fan’s research has focused on advanced life support for acute respiratory failure and patient outcomes from critical illness. These include investigations on the epidemiology and use of mechanical ventilation and extracorporeal life support in patients with ARDS, as well as on the development of ICU-acquired weakness, early rehabilitation in ICU patients, and long-term outcomes in survivors of critical illness.
Dr. Niall Ferguson is Head of Critical Care Medicine at the University Health Network and Sinai Health System, and full Professor in the Interdepartmental Division of Critical Care Medicine at the University of Toronto, with appointments in the Departments of Medicine and Physiology, and the Institute of Health Policy, Management and Evaluation at the University of Toronto. He is a Senior Scientist in the Toronto General Research Institute, and the Critical Care Lead for the Toronto-Central Local Health Integration Network. He received his M.D. with honours from the University of Toronto, and went on to complete post-graduate training in Internal Medicine, Respirology, and Critical Care Medicine. Dr. Ferguson completed a Master’s degree in Clinical Epidemiology and Health Care Research at the University of Toronto and subsequently undertook a CIHR Post-doctoral Fellowship in Madrid, Spain. He receives research funding from local, provincial, and national agencies, including the Canadian Institutes of Health Research. Dr. Ferguson’s research, which is published in high-impact journals including the New England Journal of Medicine, JAMA, and the American Journal of Respiratory & Critical Care Medicine focuses on: (1) mechanical ventilation (epidemiology; weaning and liberation; extubation and tracheostomy); (2) acute respiratory distress syndrome (definitions; ventilatory management; trial design); and (3) novel modes of mechanical ventilation, including extra-corporeal life support. Dr. Ferguson is the Scientific Programme Chair for Critical Care Canada Forum, Canada’s premier critical care conference. He is a frequent invited-speaker at national and international meetings, having given over 300 such talks.
Professor of Paediatric Tropical Infectious Diseases at the Faculty of Medicine and Director of the ICCARE Centre at the Institute for Global Health Innovation, Imperial College, London and an Honorary Fellow at MRC Clinical Trials Unit, University College, London.
Over the last 18 years, I have been based full-time in East Africa, where I lead a research group that have highlighted the unique importance of emergency-care research, previously poorly appreciated as an area for specific funder or policy investment, as a highly targeted and cost-effective means of tackling childhood mortality in resource-limited hospitals in sub-Saharan Africa. My major research portfolio includes severe malaria, bacterial sepsis and severe malnutrition and large Phase III pragmatic clinical trials in emergency care. My team conducted the largest trial in critically children ever undertaken in Africa (FEAST trial) examining fluid resuscitation strategies in children with severe febrile illness, showing that fluid boluses increased mortality compared to no-bolus (control). This went on to win the prestigious BMJ Research Paper of the Year award and led to changes in management guidelines.
David Krishna Menon is Professor and Head of the Division of Anaesthesia, and Professorial Fellow in Medicine at Queens’ College, Cambridge. He is Principal Investigator at the Wolfson Brain Imaging Centre and at the John van Geest Centre for Brain Repair in Cambridge, and Co-Chairs the Acute Brain Injury Program at the University of Cambridge. He is Chair of the European Brain Trauma Consortium and serves on the Executive of the International Neuro Trauma Society. He currently acts as Vice-Coordinator of the CENTER-TBI project, a €30 million FP7 European multicentre study of precision medicine and comparative effectiveness research in traumatic brain injury, and as Joint Director of the Cambridge NIHR Global Health Research Group on Neurotrauma. He has over a three hundred publications in peer reviewed journals, with a ‘h’ index of over 60, has contributed to major textbooks, and is one of two lead authors on a Commissioned Issue of the Lancet Neurology on Traumatic Brain Injury which was released at the European Parliament on the 7th of November 2017, and which has been used as a basis for briefing UK MPs in the All Party Parliamentary Group on Acquired Brain Injury.
Dr Adhikari is an intensivist at Sunnybrook Health Sciences Centre and assistant professor in the Interdepartmental Division of Critical Care at the University of Toronto. His research interests include critical care delivery in low-resource settings, renal replacement therapy in the ICU, and meta-analysis methods.
Ira Cheifetz, MD is the Executive Director and Chief Medical Officer for Duke Children's, Associate Chief Medical Officer for Duke University Hospital, and Vice‐Chair for Inpatient Operations in the Department of Pediatrics. He also serves as the Medical Director for Pediatric Respiratory Care Services. Dr. Cheifetz is a Professor of Pediatrics and Anesthesiology in the Duke University School of Medicine and an international expert in the fields of mechanical ventilation, respiratory monitoring, cardiorespiratory interactions, and extracorporeal life support. He has authored more than 150 peer‐reviewed publications and chapters, most of which have been in the fields of pediatric critical care and respiratory care.
Dr. Cheifetz joined the faculty of Duke University Medical Center in 1996, after completing his residency in pediatrics and a fellowship in pediatric critical care at Duke University Medical Center. He received his medical degree from Yale University School of Medicine.
Dr Conway Morris undertook undergraduate training in Glasgow, UK before moving to Edinburgh to start his training in Anaesthesia and Intensive Care. Whilst in Edinburgh he developed an interest in ICU-acquired infections and studied for a PhD in critical care immunology and its impact on nosocomial infections supervised by Professors John Simpson and Timothy Walsh. He moved to Cambridge to complete his post-graduate training in Anaesthesia and ICM and to undertake post-doctoral research with Professor Edwin Chilvers. His work continues to focus on immune failure in critical illness and nosocomial infection.
He published the first study identifying C5a as a key mediator of neutrophil dysfunction in critical illness. This has led to subsequent work developing clinically useable markers for immune dysfunction, a clinical trial of immunomodulatory therapy and exploration of the intracellular signalling pathways which underpin these effects. He has also developed a number of diagnostics for nosocomial infection, including the host response test recently evaluated in the VAP-RAPID trial, and several pathogen-focussed molecular diagnostic platforms. He is currently a Wellcome Trust Clinical Research Career Development fellow at the University of Cambridge and Consultant in Intensive Care Medicine in the John V Farman Intensive Care Unit, Addenbrooke’s Hospital, Cambridge, UK. He is the incoming Deputy Chair of the European Society of Intensive Care Medicine’s Infection section.
Charlie is one of Australia’s Australia‘s leading Intensive Care Specialists and is immediate past President of the College of Intensive Care of Australia and New Zealand.
Charlie undertook medical training at St Bartholomew’s hospital in London. He completed training as a physician and then trained as an anaesthesist. Finally he completed a third specialty program and commenced a career in intensive care.
After working in Hong Kong Charlie came to Australia, initially working as Director of Intensive Care at the Repatriation Hospital in Melbourne. In 1991 he became Director of Intensive Care in Geelong. In 2008 he stepped down as Director to concentrate more on his diverse medical interests.
Charlie is regional clinical lead for the Advance Care Planning program and is the originator of the MyValues approach to advance care planning (www.myvalues.org.au).
He lectures widely on medical communication and end-of-life decision-making. Charlie was featured on the ABC in the film ‘In the End’ and is a regular contributor to radio. He is author of ‘Letting Go’ published by Scribe, and a strong advocate of patient centred care.
Dr. Fox-Robichaud is Professor of Medicine in the Faculty of Health Sciences at McMaster University and an Intensivist and Director of Medical Education at Hamilton Health Sciences (HHS). She is the current President of the Canadian Critical Care Society and inaugural President of the Canadian Sepsis Foundation.
A clinician scientist in the Thrombosis and Atherosclerosis Research Institute at McMaster, Dr. Fox-Robichaud is particularly interested in the pathophysiology of sepsis and in moving laboratory research discoveries into clinical care. She currently holds a Collaborative Health Research Program grant to develop a point of care device for the sepsis biomarker cell free DNA. She is an executive member of the Canadian Critical Care Translational Biology Group and the Canadian Critical Care Trials Group.
In addition to her clinical and research responsibilities, Dr. Fox-Robichaud is an educator. She is the Past chair of the Critical Care Medicine examination board at the Royal College of Physicians and Surgeons of Canada. Her teaching interests include in continuing education in critical care, simulation and interprofessional teams.
In 2015, she received a Leading Practice Award from Accreditation Canada for the integration of an electronic early warning score into the medical documentation at Hamilton Health Sciences. In 2018, the Global Sepsis Alliance awarded her an individual award for her sepsis leadership. She has over 60 peer-reviewed publications that reflect this broad engagement in academic medicine.
I am head of Respirology at University Health Network and Sinai Health System and a consultant in pulmonary medicine and critical care at the Toronto General Hospital and Professor of Medicine at the University of Toronto.
I served as chair of the Ontario Thoracic Society and president of the Canadian Critical Care Society. I also recently completed a term as chair of the board of the Ontario Lung Association and remain chair of the Canadian Lung Association national fundraising advisory committee. More recently I am an active member of the Ontario Ministry of Health Lung Health Advisory panel and president elect of the Canadian Thoracic Society.
I have held leadership roles in education including tenure as program director of the U of T Critical Care Program and education director of pulmonary medicine at U of T. Over the years I developed several national and international programs in continuing medical education and received several awards for excellence in medical education.
My hospital administrative activities at UHN include chair of the pharmacy and therapeutics committee, chair of the smoking cessation strategy, member of the quality subcommittee of our hospital board and past president of the Medical Staff Association. In this latter role I developed several initiatives to promote clinician wellness.
My research interests are; pulmonary hypertension, exercise and critical illness. I am fortunate to have my work published in prominent journals including JAMA, NEJM, Lancet, American Journal of Respiratory and Critical Care Medicine and the American Journal of Respiratory and Cell Biology.
Dr. Koh is a physician scientist working as a Professor of Department of Pulmonary and Critical Care Medicine, a Professor of Department of Medical Humanities & Social Sciences, and a critical care physician at Asan Medical Center, the University of Ulsan College of Medicine in Korea. His research interests include ARDS, mechanical ventilation, sepsis, and medical ethics. He has published more than 350 articles in peer review journals.
He had served medical academy societies as a President of Korean Society of Critical Care Medicine, and a President of the Korean Society for Medical Ethics. He also had served as an organizing chairman of the 12th World Federation of Societies of Intensive and Critical Care Medicine (WFSICCM) Congress in 2015, as a council of the WFSICCM for 8 years. He had served as a chairman of the Asian Collaboration of Critical Care Trial Group. He has been contributing to enhance mechanical ventilation cares in Asia as ex-chairman of Asian Ventilation Forum.
Dr. Bram Rochwerg is an Assistant Professor in the Department of Medicine (Division of Critical Care) at McMaster University in Hamilton, Ontario, Canada with a joint appointment in the Department of Health Research Methods, Evidence and Impact. He is a practicing consultant intensivist and the clinical research lead at the Juravinski Hospital which is a large quaternary teaching hospital primarily specializing in surgical and oncologic care. Dr. Rochwerg holds the Department of Medicine Moran Campbell early career research award which provides protected time for research activities.
He is an active member of the Canadian Critical Care Trials Group and a member of the knowledge translation committee with the Canadian Critical Care Society. Dr. Rochwerg has specific scientific experience and expertise with meta-analysis, network meta-analysis, prospective observational trials, RCTs, resource utilization and clinical practice guidelines. His primary area of research is in the field of resuscitation and sepsis. He holds Hamilton Health Sciences and Physician Services Incorporated New Investigator Grants for a randomized controlled trial examining the effects of low versus high chloride intravenous fluids in ICU patients with sepsis. This multicentre RCT is currently ongoing. He is also local principle investigator for multiple national or international multicentre randomized controlled trials which are enrolling patients at the Juravinski Hospital.
Dr. Rochwerg is a GRADE clinical practice guideline (CPG) methodologist and serves as the methodologist for many CPGs for organizations such as the American Thoracic Society, the Society of Critical Care Medicine (including the Surviving Sepsis Campaign), the European Respiratory Society, the European Intensive Care Society and Canadian Blood Services.
Jeffrey Singh received his MD from the University of Toronto and subsequently specialized in Internal Medicine, Adult Critical Care Medicine and received American certification in Neurocritical Care. He has a Master’s degree in clinical epidemiology and health services research. He is currently site director of the Medical-Surgical and Neuro-Intensive Care Unit at the Toronto Western Hospital, and is an Associate Professor of Medicine at the University of Toronto.
His clinical interests involve the support of critically-ill patients with brain and spinal cord injuries, and the evolving area of organ donation science. His investigator-initiated research focuses on improving the respiratory management of acutely neurologically-injured patients has been has been funded by the Ontario Neurotrauma Foundation, Rick Hansen Institute and the PSI Foundation.
Singh also his also a Regional Medical Lead for Donation at Trillium Gift of Life Network, the organ donation organization of Canada’s most populous province. He is currently conducting several studies developing novel predictive models for organ donation after circulatory death, and evaluating novel therapies in potential organ donors to improve post-transplant organ function.
A/Prof Dianne Stephens moved from Melbourne to Darwin in 1998 as the first ICU Specialist in the region and the inaugural Director of Royal Darwin Hospital (RDH) Intensive Care Unit (ICU) and remained in this role until February 2017. She developed the RDH ICU into a nationally respected tertiary level ICU with a strong training and research culture. Dianne established the first organ donation agency in the NT and was the medical lead for organ donation for 15 years. She has published widely on sepsis, melioidosis and critical illness in the Indigenous population and has broad experience as a medical leader in clinical governance. A/Prof Stephens was elected onto the Board of CICM in 2012 and was selected to be College Censor in 2016.
A/Prof Stephens received an OAM for her leadership role in the ICU management of the 20 critically ill Bali bombing victims in 2002. She deployed to Iraq in 2004/2005 where she was Clinical Director of ICU in the USAF Hospital in Balad receiving mass casualty trauma daily and in October 2005, she deployed with the ADF to evacuate the victims of the second Bali bombings. Dianne took time for a sabbatical year in Fiji in 2016 and was living and working in Suva with her family during Cyclone Winston and its aftermath. On return to Australia in February 2017, she commenced in the new role of Medical Director of the National Critical Care and Trauma Response Centre (NCCTRC) – focusing on clinical governance, disaster training and response locally, nationally and internationally in the Asia Pacific region.
Dr. Joanna L. Stollings, Pharm.D. is the Medical Intensive Care Unit Clinical Pharmacy Specialist at the Vanderbilt University Medical Center, Nashville, Tennessee. Dr. Stollings is the pharmacist for the Post ICU Recovery Center at Vanderbilt, Vanderbilt Center for Critical Illness, Brain Dysfunction and Survivorship, and Pragmatic Critical Care Research Group. She also is Affiliate Pharmacy Faculty at Belmont University College of Pharmacy, Lipscomb University College of Pharmacy, and University of Tennessee College of Pharmacy. Dr. Stollings graduated Summa Cum Laude from West Virginia University School of Pharmacy. She then completed a Pharmacy Practice Residency at Charleston Area Medical Center in Charleston, West Virginia and a Critical Care Pharmacy Residency at Mayo Clinic in Rochester, Minnesota.
Dr. Stollings’s research interests include pharmacotherapy of agents used for analgesia, sedation, and delirium, non-pharmacologic methods used in the prevention of delirium, strategies to facilitate ventilator weaning, Post Intensive Care Syndrome, fluid resuscitation, and vasopressors. She has published over 50 peer reviewed publications and book chapters.
Dr. Stollings is an active member of the Society of Critical Care Medicine in which serves as a member at large for the Clinical Pharmacy and Pharmacology Section, member of THRIVE, the ICU Liberation Collaboration, and the Guidelines Management Committee. She is also a member of the American College of Clinical Pharmacy. She is a fellow in the American College of Critical Care Medicine and the American College of Clinical Pharmacy.
Adrian Wong is a consultant in Intensive Care Medicine and Anaesthesia in Oxford University Hospitals NHS Foundation Trust having completed a fellowship in critical care ultrasound. Graduating in 2003 from Guys and St Thomas Hospital School of Medicine, he gained MRCP before completion of Intensive Care and Anaesthetic training in 2014 in the Wessex Deanery. He is an examiner for the European Diploma of Intensive Care Medicine and a member of the ESICM Clinical Training Committee. His current areas of interest include clinical governance, critical care ultrasound and medical education.
Dr. Martin Zammert is the Director of the Cardiac Surgery Intensive Care Unit at Brigham and Women’s Hospital, Harvard Medical School in Boston, USA.
He is a cardiac anesthesiologists and also serves as the Director of Vascular Anesthesia at Brigham and Women’s Hospital.
Dr. Zammert received his medical degree from the University of Ulm, Germany.
After initial training in anesthesia at the University of Tuebingen in Germany he completed Anesthesia Residency training at Brigham and Women’s Hospital, followed by a Fellowship in Critical Care Medicine as well as a Fellowship in Cardiac Anesthesia.
Dr. Zammert is board-certified in Anesthesia, Critical Care Medicine and Advanced Perioperative transesophageal Echocardiography.
His interests are the intraoperative anesthesia management during surgery involving the aorta as well as management of patients with mechanical circulatory support in the ICU.
Awaiting for the following Speakers biography
Dr Hussain AL RAHMA
Prof Kathy ROWAN
Prof Julia WENDON
Prof Gee Young SUH
Ms Kelly THOMPSON